Senolytic drugs targeting the elimination of senescent cells have emerged as one of the most promising pharmacological approaches to extending healthspan, with the Longevity Market reflecting the rapid translation of senescence biology from laboratory discovery toward clinical trials investigating whether clearing the accumulating burden of non-dividing inflammatory senescent cells can delay age-associated diseases and extend the period of healthy functional living.

Cellular senescence — the permanent cell cycle arrest that damaged or stressed cells enter to prevent malignant transformation — serves beneficial acute functions in wound healing and embryonic development but becomes pathological when senescent cells accumulate with aging and fail to be efficiently cleared. The senescence-associated secretory phenotype, whereby senescent cells chronically secrete inflammatory cytokines, proteases, and growth factors, creates a pro-inflammatory tissue environment that drives age-related pathology in adjacent cells and distant tissues through systemic circulation.

Dasatinib and quercetin — the first senolytic combination demonstrating in vivo senescent cell elimination — established proof-of-concept in animal models and early human trials, with the Mayo Clinic-led Phase I studies demonstrating senescent cell reduction in adipose and skin tissue biopsies following short-course treatment. The intermittent dosing strategy — exploiting senescent cells' pro-survival pathway dependence through short drug exposure rather than continuous treatment — represents a practical pharmacological approach reducing adverse effect exposure while achieving senescent cell clearance.

Navitoclax, fisetin, piperlongumine, and HSP90 inhibitors represent the expanding senolytic pipeline with different mechanism profiles, selectivity, and tissue distribution characteristics that may provide superior senolytic activity in specific tissue compartments compared to the dasatinib-quercetin combination's general utility.

Do you think senolytics will demonstrate sufficient clinical benefit in age-related disease prevention trials to achieve regulatory approval as preventive longevity therapeutics within the next decade?

FAQ

What are senolytics? Senolytics are drugs that selectively eliminate senescent cells accumulating with aging, with the goal of reducing the chronic inflammatory SASP that senescent cells create and potentially delaying age-related diseases and functional decline.

What is the senescence-associated secretory phenotype? SASP is the chronic inflammatory secretion from senescent cells including cytokines, proteases, and growth factors that creates local and systemic pro-inflammatory environments driving age-related tissue dysfunction and disease progression.

#LongevityMarket #Senolytics #CellularSenescence #SASP #AgingScience #HealthspanExtension